CGRP

Biohaven on NYSE screens
Biotech

Biohaven pain spray aces test amid C-suite shake-up

Biohaven is eyeing filing for approval early next year for its experimental pain spray after data showed it hit its primary endpoints in a phase 3.
Ben Adams Dec 6, 2021 10:00am
Migraine headacheepilepsy brain image

Alder builds case for CGRP migraine drug eptinezumab

Apr 26, 2018 5:36am
Biohaven on NYSE screens

Biohaven slumps on oral migraine drug data

Mar 26, 2018 8:46am
Biohaven on NYSE screens

Biohaven pushes the gas on oral migraine drug

Nov 27, 2017 8:45am